WHOOP just became a doctor's office

WHOOP Pivots to Medicine: Telehealth, CMS Selection, and Strategic Investors

• WHOOP launched on-demand telehealth on May 12, enabling virtual visits within the WHOOP app where clinicians access biometric data, lab reports, and EHR records; two new AI features also launched: "My Memory" (centralized personal health context) and "Proactive Check-Ins" (biometrics plus personal context for tailored coaching), alongside an EHR sync via HealthEx for diagnoses, medications, and procedures (WHOOP's telehealth launch).

• WHOOP's Series G (previously reported at $575M) included strategic capital from Abbott and Mayo Clinic — not just financial investors — adding FDA regulatory expertise and clinical validation infrastructure; WHOOP was also selected for the CMS ACCESS Model, opening an insurance reimbursement pathway for technology-enabled chronic disease management among Medicare beneficiaries (Forbes's WHOOP healthcare crossover analysis).

• DC Rainmaker frames WHOOP's rapid May feature rollout as a defensive response to Fitbit Air: WHOOP has 2.5 million global users vs. Fitbit's tens of millions of active users, and WHOOP's 3-year total cost ($600–$1,070+) is roughly 2.5× the ~$400 all-in cost of Fitbit Air plus three years of Premium (DC Rainmaker's competitive cost breakdown). Strength training progression tracking — promised in 2025 — is now also shipping.

• WHOOP named official health wearable of the Boston Red Sox (2026–2028), adding Fenway Park signage and Foundation sponsorship to its sports portfolio — following previously reported PSG and Scuderia Ferrari HP deals (Red Sox partnership press release).

---

Garmin CIRQA Leaks at ~$460; Ultrahuman Ring Pro Delayed to June

• A Ukrainian retailer published a Garmin CIRQA pre-order listing at ~$454 ($509 list) today — far above the sub-$149 price analysts projected as competitive against the $99 Fitbit Air and $199 Polar Loop; the product image shows a fabric band with a Garmin logo on a visible external sensor unit (Notebookcheck's CIRQA price leak). No confirmed launch date; among screenless bands, only WHOOP MG's subscription ($359/year) exceeds this price.

• Ultrahuman Ring Pro is now shipping June 20, per Engadget's first review (8.9/10) — delayed from the May 15 date reported last issue; standout hardware includes an all-titanium body, dual-core ML chip, 12-day battery (vs. Oura Ring 4's 7 days), and a charging case with a 45-day internal cell that handles firmware updates without Bluetooth (Engadget's Ring Pro review). At $479 all-in vs. Oura's $349 + $60/year subscription, 3-year costs are roughly comparable.

• LA Times reports wearables companies now explicitly targeting disease prediction: Oura (~$11B valuation) is building AI models for hypertension; Samsung is developing dementia detection via speech and gait on Galaxy Watch; Cedars-Sinai cardiologist Dr. Joseph Schwab warns the bar for prediction "is much higher" than data gathering, and privacy data often sits outside HIPAA protections (LA Times wearables investigation).

---

Battery-Free Sweat Sensor Tracks Four Metabolic Biomarkers at Once

• UC Irvine's IREM-W2MS3, published May 13 in Nature Biomedical Engineering, is a flexible skin patch simultaneously measuring cortisol, glucose, lactate, and urea in sweat — covering stress, metabolic, exertion, and kidney function signals in one battery-free device powered via NFC from a smartphone (UC Irvine sensor announcement). Unlike last issue's vitamin sweat patch (6 nutrients, small young-adult cohort), this targets core metabolic biomarkers with validated performance over 21 continuous days under real-world pH and temperature conditions.

• The sensor surface self-regenerates via low-voltage electrical pulses, recovering near-100% electrochemical sensitivity between cycles without manual intervention; sweat is inducible via an embedded biocompatible hydrogel, enabling use without exercise (published study). Patent filed through UC Irvine's Beall Applied Innovation; no commercial timeline.

---

PBM: AMD Two-Year Trial Shows Disease Modification; Neurological Pipeline Advances

• LIGHTSITE III's 24-month data (Retina, double-blind RCT, 100 subjects/148 eyes): multiwavelength PBM via Valeda (590/660/850nm) produced +6.2 BCVA letter gain vs. sham at 21 months; critically, only 6.8% of PBM-treated eyes developed new geographic atrophy vs. 24.0% of sham at 24 months (p=0.007), a potential disease-modification signal beyond visual acuity improvement (LIGHTSITE III 24-month results). Issue #1 reported the 13-month visual acuity data; the GA progression reduction is new.

• A 12-week home-based transcranial PBM RCT (Journal of Alzheimer's Disease, n=80) found 808nm NIR light produced a mean MoCA-K improvement of +3.87 points vs. a −0.74-point decline in placebo (p<0.001) in MCI-due-to-Alzheimer's patients — a 3-point MoCA change is the established clinical significance threshold (published trial PMID 42024020). Small sample, 12-week duration; home-compatible device format.

• A 5-year PBM follow-up in Parkinson's disease, published in 2026, shows sustained improvements in mobility, balance, cognition, and olfaction with continuous NIR treatment and no serious safety concerns — the longest PBM-PD clinical follow-up to date; larger confirmatory trials are still needed (APDA's light therapy in PD overview). NIR (700–1300nm) penetrates the skull more effectively than red light (620–750nm) for neurological targets.

• A double-blind RCT in Climacteric (PMID 42060269) found 808nm vaginal laser PBM significantly reduced urinary leakage and vaginal dryness in postmenopausal women with Genitourinary Syndrome of Menopause, via collagen synthesis and tissue vascularity improvements — an alternative for women who cannot use hormone therapy (published RCT PMID 42060269). Clinical procedure; not a home device application.

---

Contrast Therapy: Recalibrating Protocols for Women as Market Scales

• Experts interviewed by Hello! now recommend women treat contrast therapy as "vascular training," not an endurance test: a beginner protocol of 10–15 minutes of heat + 30–90 seconds of cold (2–3 rounds) is advised over the extended protocols extrapolated from male athletic data, since women make up only 12–18% of thermoregulation study participants (Hello! Magazine's expert roundup). Neuroscientist Alanna Kit notes consistency matters more than intensity; some practitioners advise reducing cold intensity during the luteal phase, though phase-specific RCT data is absent.

• The U.S. sauna industry was valued at $197.6M in 2024, projected to reach $311.4M by 2033; the global cold plunge market is projected to reach ~$2B by 2035, with North America holding the largest revenue share (Nordic wellness market report).